Symbols / CRDF Stock $1.63 -0.61% Cardiff Oncology, Inc.

Healthcare • Biotechnology • United States • NCM
CRDF (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Mani Mohindru Ph.D.
Exch · Country NCM · United States
Market Cap 111.44M
Enterprise Value 54.65M
Income -45.88M
Sales 593.00K
FCF (ttm) -19.62M
Book/sh 0.66
Cash/sh 0.85
Employees 30
Insider 10d —
IPO Jul 27, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.33
PEG —
P/S 187.93
P/B 2.45
P/C —
EV/EBITDA -1.12
EV/Sales 92.15
Quick Ratio 3.59
Current Ratio 3.67
Debt/Eq 1.83
LT Debt/Eq —
EPS (ttm) -0.69
EPS next Y -0.70
EPS Growth —
Revenue Growth 60.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-02-24
ROA -38.47%
ROE -71.45%
ROIC —
Gross Margin 0.00%
Oper. Margin -32.21%
Profit Margin 0.00%
Shs Outstand 68.37M
Shs Float 66.71M
Insider Own 5.91%
Instit Own 35.59%
Short Float 27.50%
Short Ratio 26.86
Short Interest 18.32M
52W High 4.56
vs 52W High -64.25%
52W Low 1.48
vs 52W Low 10.14%
Beta 1.36
Impl. Vol. 1.92%
Rel Volume 0.83
Avg Volume 693.34K
Volume 576.52K
Target (mean) $7.75
Tgt Median $9.25
Tgt Low $2.00
Tgt High $12.00
# Analysts 8
Recom None
Prev Close $1.64
Price $1.63
Change -0.61%
About

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.75
Mean price target
2. Current target
$1.63
Latest analyst target
3. DCF / Fair value
$-5.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.63
Low
$2.00
High
$12.00
Mean
$7.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-25 main Piper Sandler Overweight → Overweight $6
2026-01-28 reit HC Wainwright & Co. Buy → Buy $10
2025-08-06 main HC Wainwright & Co. Buy → Buy $10
2025-07-08 init Ladenburg Thalmann — → Buy $19
2025-06-24 init Jefferies — → Hold $4
2025-05-09 main HC Wainwright & Co. Buy → Buy $18
2025-02-28 main HC Wainwright & Co. Buy → Buy $17
2024-12-13 main Piper Sandler Overweight → Overweight $10
2024-11-08 main HC Wainwright & Co. Buy → Buy $13
2024-09-06 init Craig-Hallum — → Buy $8
2024-05-06 reit HC Wainwright & Co. Buy → Buy $14
2024-03-06 main HC Wainwright & Co. Buy → Buy $14
2024-03-01 main Piper Sandler Overweight → Overweight $7
2023-08-11 main HC Wainwright & Co. Buy → Buy $12
2023-08-08 main HC Wainwright & Co. Buy → Buy $13
2023-05-09 main HC Wainwright & Co. — → Buy $14
2023-03-29 reit HC Wainwright & Co. — → Buy $15
2023-03-07 main HC Wainwright & Co. — → Buy $15
2022-09-16 main HC Wainwright & Co. — → Buy $14
2022-09-13 main Piper Sandler — → Overweight $5
News
RSS: Latest CRDF news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2020-01-02 ERLANDER MARK Officer — 261 — —
2020-01-01 ERLANDER MARK Officer — 1,250 — —
2019-10-01 ERLANDER MARK Officer — 1,250 — —
2019-07-01 ERLANDER MARK Officer — 1,250 — —
2019-04-01 ERLANDER MARK Officer — 1,250 — —
2019-01-02 ERLANDER MARK Officer — 1,563 — —
2019-01-01 ERLANDER MARK Officer — 7,500 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.59
-13.18%
0.68
+39.96%
0.49
+26.42%
0.39
Operating Revenue
0.59
-13.18%
0.68
+39.96%
0.49
+26.42%
0.39
Operating Expense
49.55
+0.44%
49.33
+7.48%
45.90
+13.93%
40.29
Research And Development
35.33
-4.13%
36.85
+12.16%
32.86
+21.21%
27.11
Selling General And Administration
14.22
+13.96%
12.48
-4.30%
13.04
-1.05%
13.18
General And Administrative Expense
14.22
+13.96%
12.48
-4.30%
13.04
-1.05%
13.18
Salaries And Wages
7.29
+14.16%
6.39
-5.55%
6.76
+6.39%
6.36
Other Gand A
6.93
+13.75%
6.10
-2.96%
6.28
-7.97%
6.83
Total Expenses
49.55
+0.44%
49.33
+7.48%
45.90
+13.93%
40.29
Operating Income
-48.96
-0.64%
-48.65
-7.13%
-45.41
-13.81%
-39.90
Total Operating Income As Reported
-48.96
-0.64%
-48.65
-7.13%
-45.41
-13.81%
-39.90
EBITDA
-48.06
-0.73%
-47.71
-5.98%
-45.01
-13.48%
-39.67
Normalized EBITDA
-48.06
-0.73%
-47.71
-5.98%
-45.01
-13.48%
-39.67
Reconciled Depreciation
0.90
-4.14%
0.94
+136.93%
0.40
+68.64%
0.24
EBIT
-48.96
-0.64%
-48.65
-7.13%
-45.41
-13.81%
-39.90
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Net Income
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Pretax Income
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Net Non Operating Interest Income Expense
3.10
-4.76%
3.26
-19.91%
4.07
+157.37%
1.58
Interest Expense Non Operating
—
—
—
—
Net Interest Income
3.10
-4.76%
3.26
-19.91%
4.07
+157.37%
1.58
Interest Expense
—
—
—
—
Interest Income Non Operating
3.10
-4.76%
3.26
-19.91%
4.07
+157.37%
1.58
Interest Income
3.10
-4.76%
3.26
-19.91%
4.07
+157.37%
1.58
Other Income Expense
0.01
+112.82%
-0.04
+60.20%
-0.10
+74.41%
-0.38
Other Non Operating Income Expenses
0.01
+112.82%
-0.04
+60.20%
-0.10
+74.41%
-0.38
Gain On Sale Of Security
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Net Income From Continuing Operation Net Minority Interest
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Net Income From Continuing And Discontinued Operation
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Net Income Continuous Operations
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Normalized Income
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Net Income Common Stockholders
-45.88
-0.93%
-45.45
-9.62%
-41.47
-7.07%
-38.73
Diluted EPS
-0.69
+27.37%
-0.95
-2.15%
-0.93
-4.49%
-0.89
Basic EPS
-0.69
+27.37%
-0.95
-2.15%
-0.93
-4.49%
-0.89
Basic Average Shares
66.84
+40.27%
47.65
+6.65%
44.68
+2.47%
43.60
Diluted Average Shares
66.84
+40.27%
47.65
+6.65%
44.68
+2.47%
43.60
Diluted NI Availto Com Stockholders
-45.88
-0.93%
-45.45
-9.62%
-41.47
-7.07%
-38.73
Preferred Stock Dividends
0.03
+4.17%
0.02
+0.00%
0.02
+0.00%
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
61.88
-36.33%
97.19
+19.05%
81.64
-29.74%
116.19
Current Assets
60.13
-36.74%
95.05
+22.79%
77.41
-30.44%
111.28
Cash Cash Equivalents And Short Term Investments
58.30
-36.45%
91.75
+22.62%
74.82
-28.92%
105.27
Cash And Cash Equivalents
17.47
-66.06%
51.47
+137.68%
21.66
+32.47%
16.35
Other Short Term Investments
40.83
+1.39%
40.28
-24.25%
53.17
-40.21%
88.92
Receivables
0.18
-76.46%
0.77
+168.40%
0.29
-62.65%
0.77
Accounts Receivable
0.18
-76.46%
0.77
+168.40%
0.29
-62.65%
0.77
Prepaid Assets
—
—
—
—
Other Current Assets
1.64
-35.23%
2.54
+10.17%
2.30
-56.14%
5.25
Total Non Current Assets
1.76
-17.79%
2.14
-49.44%
4.22
-13.90%
4.91
Net PPE
1.21
-41.61%
2.07
-29.84%
2.95
-16.31%
3.52
Gross PPE
5.67
-8.54%
6.20
-7.38%
6.70
-3.39%
6.93
Accumulated Depreciation
-4.47
-7.98%
-4.14
-10.26%
-3.75
-9.93%
-3.41
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.05
-0.19%
1.05
-1.31%
1.07
+0.09%
1.07
Other Properties
2.06
-20.44%
2.58
-15.67%
3.06
-7.38%
3.31
Leases
2.57
+0.00%
2.57
+0.00%
2.57
+0.31%
2.56
Other Non Current Assets
0.55
+695.65%
0.07
-94.61%
1.28
-7.79%
1.39
Total Liabilities Net Minority Interest
16.50
+15.83%
14.24
+19.69%
11.90
+20.82%
9.85
Current Liabilities
16.39
+22.09%
13.43
+28.62%
10.44
+33.71%
7.81
Payables And Accrued Expenses
13.23
+32.71%
9.97
+42.21%
7.01
+32.70%
5.28
Payables
8.83
+83.18%
4.82
+145.22%
1.97
+0.51%
1.96
Accounts Payable
8.09
+67.75%
4.82
+145.22%
1.97
+0.51%
1.96
Other Payable
0.74
—
—
—
Dividends Payable
—
—
—
0.00
Current Accrued Expenses
4.40
-14.52%
5.15
+2.08%
5.05
+51.62%
3.33
Pensionand Other Post Retirement Benefit Plans Current
2.43
-11.51%
2.75
+0.33%
2.74
+48.03%
1.85
Current Debt And Capital Lease Obligation
0.73
+2.82%
0.71
+2.75%
0.69
+2.37%
0.68
Current Capital Lease Obligation
0.73
+2.82%
0.71
+2.75%
0.69
+2.37%
0.68
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
0.10
-87.45%
0.81
-44.24%
1.46
-28.53%
2.04
Long Term Debt And Capital Lease Obligation
0.10
-87.45%
0.81
-44.24%
1.46
-28.53%
2.04
Long Term Capital Lease Obligation
0.10
-87.45%
0.81
-44.24%
1.46
-28.53%
2.04
Stockholders Equity
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Common Stock Equity
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Capital Stock
0.01
+0.00%
0.01
+75.00%
0.00
+0.00%
0.00
Common Stock
0.01
+0.00%
0.01
+75.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
68.31
+2.68%
66.52
+48.90%
44.68
+0.00%
44.68
Ordinary Shares Number
68.31
+2.68%
66.52
+48.90%
44.68
+0.00%
44.68
Additional Paid In Capital
475.36
+1.77%
467.09
+14.11%
409.34
+1.11%
404.83
Retained Earnings
-430.03
-11.93%
-384.18
-13.15%
-339.54
-13.90%
-298.10
Gains Losses Not Affecting Retained Earnings
0.05
+47.06%
0.03
+150.75%
-0.07
+83.04%
-0.40
Other Equity Adjustments
0.05
+47.06%
0.03
+150.75%
-0.07
+83.04%
-0.40
Total Equity Gross Minority Interest
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Total Capitalization
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Working Capital
43.73
-46.42%
81.63
+21.88%
66.97
-35.28%
103.48
Invested Capital
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Total Debt
0.83
-45.37%
1.52
-29.13%
2.15
-20.85%
2.71
Capital Lease Obligations
0.83
-45.37%
1.52
-29.13%
2.15
-20.85%
2.71
Net Tangible Assets
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Tangible Book Value
45.39
-45.28%
82.95
+18.94%
69.74
-34.42%
106.34
Derivative Product Liabilities
—
—
—
—
Other Equity Interest
—
—
—
—
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-37.92
-0.61%
-37.69
-22.04%
-30.89
+8.67%
-33.82
Cash Flow From Continuing Operating Activities
-37.92
-0.61%
-37.69
-22.04%
-30.89
+8.67%
-33.82
Net Income From Continuing Operations
-45.85
-0.92%
-45.43
-9.63%
-41.44
-7.07%
-38.70
Depreciation Amortization Depletion
0.90
-4.14%
0.94
+136.93%
0.40
+68.64%
0.24
Depreciation
0.90
-4.14%
0.94
+136.93%
0.40
+68.64%
0.24
Depreciation And Amortization
0.90
-4.14%
0.94
+136.93%
0.40
+68.64%
0.24
Other Non Cash Items
—
—
—
0.14
Stock Based Compensation
5.69
+19.60%
4.76
+5.57%
4.51
+5.94%
4.26
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
—
—
—
0.00
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
2.18
-17.24%
2.63
-59.91%
6.57
+1828.42%
-0.38
Change In Receivables
0.59
+222.11%
-0.48
-200.21%
0.48
+304.66%
-0.24
Change In Prepaid Assets
0.56
+223.23%
-0.45
-114.26%
3.17
+815.35%
-0.44
Change In Payables And Accrued Expense
2.20
-26.23%
2.98
+5.44%
2.83
+110.01%
1.35
Change In Other Current Assets
-0.48
-139.67%
1.21
+85.87%
0.65
+207.96%
-0.60
Change In Other Current Liabilities
-0.69
-10.38%
-0.63
-10.60%
-0.57
-26.91%
-0.45
Investing Cash Flow
1.34
-90.22%
13.73
-62.07%
36.20
-5.12%
38.15
Cash Flow From Continuing Investing Activities
1.34
-90.22%
13.73
-62.07%
36.20
-5.12%
38.15
Capital Expenditure
-0.04
+45.00%
-0.08
+86.25%
-0.58
+42.15%
-1.01
Capital Expenditure Reported
-0.04
+45.00%
-0.08
+86.25%
-0.58
+42.15%
-1.01
Net Investment Purchase And Sale
1.39
-89.96%
13.81
-62.45%
36.78
-5.80%
39.04
Purchase Of Investment
-71.86
-204.97%
-23.56
+66.38%
-70.08
+23.18%
-91.23
Sale Of Investment
73.25
+96.00%
37.37
-65.03%
106.86
-17.97%
130.27
Net Other Investing Changes
—
—
—
0.11
Financing Cash Flow
2.58
-95.20%
53.78
0.00
-100.00%
0.07
Cash Flow From Continuing Financing Activities
2.58
-95.20%
53.78
0.00
-100.00%
0.07
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
-100.00%
53.41
0.00
0.00
Proceeds From Stock Option Exercised
2.58
+591.96%
0.37
0.00
-100.00%
0.07
Changes In Cash
-34.00
-214.04%
29.82
+461.70%
5.31
+20.53%
4.40
Beginning Cash Position
51.47
+137.68%
21.66
+32.47%
16.35
+36.88%
11.94
End Cash Position
17.47
-66.06%
51.47
+137.68%
21.66
+32.47%
16.35
Free Cash Flow
-37.97
-0.51%
-37.77
-20.03%
-31.47
+9.64%
-34.83
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
+0.00%
0.00
-50.00%
0.00
Amortization Of Securities
-0.85
-41.81%
-0.60
+35.07%
-0.92
-245.73%
0.63
Common Stock Issuance
0.00
-100.00%
53.41
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
53.41
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category